Olema Pharmaceuticals, Inc.
Olema Oncology develops estrogen receptor antagonists and degraders for breast cancer.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story
Olema Oncology develops estrogen receptor antagonists and degraders for breast cancer.
November 2026
October 2026
August 2026